Sign In
Buy CBIO
$17.98
+0.98 (+5.73%)
At Close: Jun 03, 2026
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Average Recommendation of “Buy” by Brokerages
04:08am, Monday, 02'nd Feb 2026
Shares of Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) have received a consensus recommendation of "Buy" from the nine brokerages that are presently covering the firm, MarketBeat.com repo
Crescent Biopharma Announces Grants of Inducement Awards
04:05pm, Friday, 30'th Jan 2026
WALTHAM, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing t
CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with proof-of-con
Crescent Biopharma Announces Grants of Inducement Awards
04:15pm, Thursday, 18'th Dec 2025
WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of
Market Today: IBM buys Confluent; Nvidia wins China chip nod
05:33pm, Monday, 08'th Dec 2025
Stock News Paramount escalates WBD fight: Paramount Skydance (PSKY) launched a hostile all-cash $30 per share tender offer for Warner Bros. Discovery (WBD), val
Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs), generating clinical d
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
06:30am, Thursday, 04'th Dec 2025
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of “Buy” from Analysts
03:10am, Wednesday, 19'th Nov 2025
Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) has been given a consensus recommendation of "Buy" by the seven ratings firms that are currently covering the firm, Marketbeat.com reports. On
Crescent Biopharma Announces Grants of Inducement Awards
04:15pm, Monday, 17'th Nov 2025
WALTHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
07:30am, Thursday, 06'th Nov 2025
IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the Pi
Crescent Biopharma to Present at November Investor Conferences
07:30am, Wednesday, 05'th Nov 2025
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of
CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients wi
Crescent Biopharma to Present at September Investor Conferences
07:30am, Thursday, 28'th Aug 2025
WALTHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of
Crescent Biopharma: Chasing The Summit Hype
11:33am, Monday, 18'th Aug 2025
Crescent Biopharma is an early-stage biotech with a promising PD-1/VEGF bispecific antibody, aiming for first-in-human trials in late 2025. The company is well-funded, with over $150 million in cash a
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
07:34am, Thursday, 31'st Jul 2025
Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors
